r-pharm company overview - jefferies pharm jsc.pdf · successful transformation from distribution...
TRANSCRIPT
www.r-pharm.com
R-PHARM – COMPANY OVERVIEWJune, 2017
Jefferies 2017
Health Care Conference
June 9, 2017
Demetrios Kydonieus, President & CBO
1
R-Pharm Key Facts
Established in 2001, 100% private.
The leading Russian vertically integrated
specialty care pharmaceutical company.
Products from a broad range of
specialty/hospital care therapeutic areas.
Preferred partner for global Pharma
leaders.
3,500+ employees at 50+ branches.
Presence in 9 countries.
RUR 77,6+ bn revenue in 2015.
Research &
Development
Manufacturing
Marketing & Sales
Distribution
2
Management Team
Ivan Semenov
VP HR and OD
Kathrin Abelein
VP Quality
Tuygan Goker
President
TR-Pharm
Mikhail Samsonov
Chief Medical Officer
Yan Lavrovsky
CSO, CEO
R-Pharm Overseas
Vasily Ignatiev
Chief Executive Officer
Alexey Repik
Chairman, Founder
Mark Pavao
President and CEO
R-Pharm US LLC
Valeria Povolotsky
VP – Global Partnering
Andrey Smirnov
Chief Financial Officer
Holger Weyhers
Managing Director
R-Pharm Germany
Demetrios Kydonieus
President and CBO
R-Pharm US LLC
Alexey Ordzhonikidze
VP External Affairs
Chris Posner
VP Immunology
Valery Pereletov
VP – Commercial Affairs
3
Solid Growth Despite Market Volatility
R-Pharm
Others
2015
25%
75%
31.3 39.3 41.946.1
60.8
77.6
30 29.325.5
21.3 24.3
31.8
0
1016.4
24.836.5
45.8
2010 2011 2012 2013 2014 2015
R-Pharm sales volume
Sales volume
Distribution
R&D, manufacturing and S&M
Billion
Rubles
Hospital & Reimbursement
Segment (Russia)
The leading position
in public procurement
Note: R-Pharm data
Strong double digit sales growth including 2015, despite slower domestic market growth.
Successful transformation from distribution to a fully vertically integrated specialty pharma.
Integration strategy plus portfolio transformation significantly increased profitability.
4
Functional/Therapeutic Areas
• R&D
• Manufacturing
• Distribution
• Market Access
• Promotion
• Oncology
• Antivirals
• Antibiotics
• Neurology
• Immunology
• Vaccines
• Diabetes
• Acute care cardiology
• Orphan diseases
5
6
Oncology
Avastin
Beyodym
Herceptin
Kadcyla
Keytruda
Sprycel
Tarceva
Xeloda
HIV / AIDS / Hepatitis
treatment
Baraclude
Daklinza
Isentress
Kaletra
Reyataz
Sebivo
Viekira Pak
Antibiotics
Cubicin
Invanz
Spectracef
Tienam
Vibativ
HumiraAnti-inflammatory
Other Aubagio
De-Nol
Duodopa
Humalog
Prograf
Therapeutic area Partner Company Products
Over 70 In-Licensed / Co-Promoted Products
7
R-Pharm value proposition Current partners
Unmatched commercialization
power in Russia, EEU and CIS,
and beyond
Compliant partner with strong
reputation.
Very experienced commercial
groups in Russia, EEU & CIS,
Turkey/MENA and US driving
partnering deals.
Highly professional Development
& Regulatory, with fast track
opportunities.
State of the art manufacturing
(Solid forms, Sterile F&F,
Biologics, API).
Develo
pm
en
tM
an
ufa
ctu
rin
gP
rom
oti
on
R-Pharm Partnering Strengths
Three Strategic Pillars
Continue the pathway of transformation.
Invest in new R&D projects.
Pursue leading edge in manufacturing in Russia.
Create new therapeutic area specific partnerships/JVs with
multinational players.
Invest in a healthy & robust product pipeline.
13 in-licensed and 7 own attractive products currently under
development – 5 currently in registration.
Strengthening of
the fully integrated
value-chain in Russia/EEU/CIS
Geographical expansion
to realize full commercial
potential
Investment in innovative
product portfolio
Build broader geographic footprint – R-Pharm today present
in 9 countries and further expansion planned.
Grow outside Russia to realize full product potential.
Become closer to existing & new partners for new business
opportunities.
Become the first fully integrated Russian
pharma player with global footprint
1
2
3
8
Robust Pipeline
R-Pharm
Pipeline
In-licensed
pipeline
Cell line &process
developmentPre-Clinical
Clinicalstudies
Filing /registration ProductTA
Oncology
Anti-infective
&
antiviral
Anti-
inflammatory
Others
RPH 001
RPH 002
RPH 203
RPH 120
Olokizumab
RPH 104
RPH 007
Remimazolam
Narlaprevir
Nemonoxacin
Odelepran
SCY 078
Fimasartan
Cefilavancin
Radotinib
Imidafenacin
Ixabepilone
ONC1-0013B
Marketed
Telavancin Marketed
9
Selected Pipeline Highlights
Product Description/Status
Olokizumab
RPH-203
Globally patented osteoprotegrin-IgG1 (Fc) fusion protein –
RANKL inhibitor.
Treatment for tumor-related bone lytic lesions, giant cell bone
tumors, etc.
Phase I completed, Phase II clinical trial initiated in Oct 2015.
RPH-104
Globally patented novel recombinant heterodimer nanoprotein.
Inhibits IL-1β/IL-1F2-induced signaling.
FIH study initiated in Jan 2016.
Target indications: FMF, Behcet’s disease.
Globally licensed anti-IL-6 MAB for RA and other indications.
Solid and sustained efficacy in difficult to treat subgroups (anti-
TNF-NRs) in phase II.
Completed FDA (CMC, EOP2) and EMA (SAWP) consultations.
International phase III program initiated in May 2016.
10
Geographic Expansion
2013 majority
owned affiliate set
up in Turkey
R-Pharm with local activities
2010 R&D
partnership in
India established
2013 launch of
research collaboration
in Japan
2014 acquisition of a
manufacturing
asset in Germany
2014 R-Pharm US LLC
est. in the US
2014 API and F&F
site in Turkey
being designed
2011 R&D and BD
company est. in the US
2014 Commercial
entity established
in UAE
11
R-Pharm US: Specialty
BioPharma Business for the Americas
Key Facts:
• Founded in 2014 in Princeton, NJ.
• Focus: Oncology, Immunology and Specialty Diseases.
• Ixempra for aggressive metastatic or locally advanced breast cancer
acquired from BMS, (global rights).
• Fully integrated commercialization team over 50 FTEs.
• 2016 sales estimated at $45M.
Strategy:
• Phase 1: Acquire underserved medicines and maximize their potential
through efficient, innovative commercialization.
• Phase 2: Leverage commercialization infrastructure to successfully
launch R-Pharm JSC developed medicines.
12
R-Pharm US Portfolio 13
Ixempra*
• Acquired from Bristol-Myers Squibb in 2015
• Indicated for metastatic breast cancer
• Fully dedicated commercialization in USA
• Distribution partners for 11 ex-US markets
Episil*
• Licensed from Camurus AB in 2016
• Fully dedicated commercialization in USA
• Indicated for oral mucositis
Zuplenz* and Oravig*
• 2016 US co-promotion with Midatech
• Supportive care brands complementary to
Ixempra and Episil
* See product website for full prescribing information
www.ixempra.com
www.episilusa.com
www.zuplenz.com
www.oravig.com
Three Strategic Pillars
Strengthening of
the fully integrated
value-chain in Russia/EEU/CIS
Geographical expansion
to realize full commercial
potential
Investment in innovative
product portfolio
Become the first fully integrated Russian
pharma player with global footprint
14
